European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Home
/
insight
/
details

MSI: A Catalyst for Personalized Cancer Care and Therapeutic Innovation

NextEdge Admin

05 May 2024

3 min 7 sec

Microsatellite instability (MSI) is a phenomenon crucial in understanding certain aspects of cancer biology and treatment. At its core, MSI reflects a malfunction in the cell’s ability to repair errors that occur during DNA replication, particularly in short repeating sequences called microsatellites. These sequences, akin to genetic fingerprints, are normally stable due to the cell’s meticulous error-correction mechanisms. However, when these mechanisms falter, as in cases of mismatch repair deficiency, microsatellites become unstable.

In cancer, MSI holds significant implications. While once considered a harbinger of poor prognosis in advanced cancers, recent advancements in immunotherapy have reshaped this narrative. MSI-high cancers, characterized by rampant mutations and protein alterations, become more visible to the immune system. This heightened immunogenicity renders them susceptible to immunotherapeutic interventions, offering new hope for patients previously facing limited treatment options.

Clinically, identifying MSI has become increasingly important, particularly in colorectal cancer where universal testing is now standard practice. Though MSI remains relatively rare across cancer types, its impact on treatment outcomes underscores the necessity for broader screening efforts. As our understanding of MSI continues to evolve, so does its role in shaping personalized cancer care.

Selecting the best method for testing microsatellite instability (MSI) hinges on factors like sensitivity, specificity, and resource accessibility. PCR-based assays offer cost-effective, high sensitivity, but require specialized equipment. Immunohistochemistry (IHC) provides direct MMR protein expression evidence and is widely available. Next-generation sequencing (NGS) offers comprehensive genomic analysis but demands specialized expertise and equipment. Combining methods, such as PCR and IHC, can bolster MSI detection accuracy and clinical decision-making, facilitating a tailored approach based on the unique needs of each clinical scenario.

MSI exemplifies the intricate interplay between genetics, tumor biology, and therapeutic innovation. Its recognition not only illuminates the underlying mechanisms driving cancer progression but also heralds a promising era in precision oncology, where tailored treatments capitalize on the vulnerabilities inherent in tumor biology.